Influence of the glass packing on the contamination of pharmaceutical products by aluminium. Part I: Salts, glucose, heparin and albumin

被引:21
作者
Bohrer, D [1 ]
do Nascimento, PC [1 ]
Binotto, R [1 ]
Pomblum, SC [1 ]
机构
[1] Univ Fed Santa Maria, Dept Quim, BR-97110900 Santa Maria, RS, Brazil
关键词
aluminium contamination; glass containers; heparin; albumin; glucose; salts;
D O I
10.1016/S0946-672X(01)80050-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
The presence of aluminium (Al) in pharmaceutical products used parenterally as sodium and potassium chlorides, glucose, heparin and albumin were investigated with respect to their storage in glass containers. As glasses can have aluminium in their composition, the aluminium may be released from the glass into the solution. The action of the substances above mentioned were investigated storing their solutions in glass and plastic containers, and measuring the aluminium in solution at determined time intervals. The aluminium present in the commercial pharmaceutical products, stored in both plastic and glass containers were also measured. All glass containers were analysed to determine their aluminium content. The aluminium determinations were done by atomic absorption spectrometry. The results showed that aluminium is present in all analysed glasses in a percentage of 0.6 to 3%. Although all substances already have a residual aluminium contamination, the major contribution comes from the glass containers in which their solutions were stored. The contamination arising from glass depends too much on the nature of the substance. While the salts extracted about 400 mug Al/l in 60 days, glucose extracted 150 mug Al/l, and albumin and heparin about 500 mug Al/l in the same time interval. Commercial solutions of glucose contain about 10 mug Al/l when stored in polyethylene and from 350 to 1000 mug Al/l when in glass ampules. Considering all commercial products, solutions stored in plastic containers contained no more than 20 mug Al/l whereas in glass the aluminium contamination reached 1000 mug/l, and in all of them the aluminium increases with the age of the product.
引用
收藏
页码:95 / 101
页数:7
相关论文
共 23 条
[1]
ALUMINUM TOXICITY IN PATIENTS WITH CHRONIC-RENAL-FAILURE [J].
ALFREY, AC .
THERAPEUTIC DRUG MONITORING, 1993, 15 (06) :593-597
[2]
Aluminum in enteral nutrition formulas and parenteral solutions [J].
Baydar, T ;
Aydin, A ;
Duru, S ;
Isimer, A ;
Sahin, G .
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1997, 35 (03) :277-281
[3]
On-line separation and spectrophotometric determination of low levels of aluminum in high-salt content samples: application to analysis of hemodialysis fluids [J].
Bohrer, D ;
Gioda, A ;
Binotto, R ;
do Nascimento, PC .
ANALYTICA CHIMICA ACTA, 1998, 362 (2-3) :163-169
[4]
BOHRER D, 1997, QUIM NOVA, V20, P407
[5]
GAMMELGAARD B, 1989, J TRACE ELEM ELECT H, V3, P39
[6]
Aluminum exposure and metabolism [J].
Greger, JL ;
Sutherland, JE .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 1997, 34 (05) :439-474
[7]
Kelly A T, 1989, ASAIO Trans, V35, P674, DOI 10.1097/00002480-198907000-00164
[8]
ALUMINUM IN PARENTERAL SOLUTIONS REVISITED - AGAIN [J].
KLEIN, GL .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1995, 61 (03) :449-456
[9]
PARENTERAL DRUG PRODUCTS CONTAINING ALUMINUM AS AN INGREDIENT OR A CONTAMINANT - RESPONSE TO FDA NOTICE OF INTENT [J].
KLEIN, GL .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1991, 53 (02) :399-402
[10]
KLEIN GL, 1991, NUTR REV, V49, P74, DOI 10.1111/j.1753-4887.1991.tb07409.x